Design and Evaluation of the Effects of a Physical Therapy Program With Digital Support in Patients With Breast Cancer

February 24, 2025 updated by: Ana Belén Romojaro Rodríguez, Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Design and Evaluation of the Effects of a Physical Therapy Program With Digital Support in Patients With Breast Cancer Surgery. A Clinical Trial.

Breast cancer surgery usually results in reduced range of motion of the shoulder joint, weakness of the musculature and altered scapular kinematics during movement. These factors limit activities of daily living, so rehabilitation exercises help to restore function after shoulder surgery.

Women with breast cancer often have a life conditioned by the sequelae or morbidity secondary to the treatment of the disease and, despite the high cure rate, many patients are unable to regain their initial quality of life. Cancer therapies can leave physical, psychological and psychosocial sequelae, which may manifest themselves or persist even years after the end of treatment.

For all these reasons, patients who have undergone cancer treatment need physical rehabilitation as well as psychological and social care to support them in their new stage of life, and to optimise the rehabilitation programme, it is necessary to identify each patient's individual needs,

The digital support proposed in this study enables the development of a physiotherapy programme for patients with breast cancer in a situation of health crisis, which includes providing assistance, information, accompaniment, help and treatment to these patients in a comprehensive way, based on the biopsychosocial model.

Study Overview

Detailed Description

DESIGN: Single-centre, assessor-blinded, parallel-group, randomised controlled clinical trial.

METHODS: The study will be carried out at the Ramon y Cajal hospital with 92 patients diagnosed and operated on for breast cancer.

Patients who come to the consultation of the rehabilitation doctors will be assessed, considering the inclusion and exclusion criteria. Those who may be candidates will be informed about the study and referred to the physiotherapy department where the treatment orders for these patients will be received and an appointment will be made. This is the start of the recruitment phase.

Those who meet the criteria and agree to participate in the study will be assigned an identification code and will be randomised into the two groups, the intervention group and the conventional treatment group.

Patients who do not meet the inclusion criteria or refuse to participate in the study will receive conventional treatment.

A 6-month pilot study will be conducted to better define patient identification, inclusion criteria, recruitment and adjustment of the intervention if required.

Once the pilot study is completed, the intervention clinical trial will begin. A first analysis of all variables will be performed after the intervention phase of the trial, 6 weeks after inclusion in the study.

An interim analysis will also be performed at 3 months in which the same variables as at 6 weeks will be assessed. This will be the main analysis of the study.

The final analysis will be carried out 6 months after inclusion in the study, and this will conclude the follow-up phase.

Study Type

Interventional

Enrollment (Actual)

92

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Madrid, Spain, 28834
        • Fundacion Hospital Ramón y Cajal

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Diagnosis of stage I, II or III of Breast cancer treated by surgery.
  • Medical authorisation for participation.
  • Internet access.
  • Basic computer skills.
  • Signed informed consent.
  • No bilateral mastectomy.
  • No metastases.
  • Post-intervention period of 10 days to 3 months.
  • Age 18-85 years.
  • No previous shoulder pathologies.
  • No pathology that prevents exercise.
  • Understanding of the Spanish language.

Exclusion Criteria:

  • Breast cancer treated without surgery.
  • Patient in severe psychiatric treatment who may present difficulties for participation in the study.
  • Stage IV cancer.
  • Any other clinical condition or previous therapy that contraindicates one or more of the techniques included in the programme, as the intervention may not be safe for the patient and therefore the person would not be eligible to participate in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group 1. Conventional treatment
Patients will be treated with a physiotherapy programme without digital support.

Patients will be treated using a physiotherapy programme without digital support. A written document with exercises and recommendations will be given to them on the first day. This booklet will detail the exercises they can do depending on their surgery and the weeks elapsed, as well as the recommendations adapted according to the needs identified in the motivational interview (MI). This is the treatment that is currently being applied in the hospital.

The patient will carry out the treatment at home and will come back after 20 sessions for the corresponding assessment.

Experimental: Group 2. Experimental treatment.
Patients will be treated using a digitally supported physiotherapy programme.

A digitally supported physiotherapy programme including:

  • Group session: expectations, interests, experiences with regard to their health problem and the consequences on their life, joint exercise and discussion with subsequent debate will be held.
  • Exercise session: each week, patients will find different exercise videos on the platform according to the phase of recovery in which each one of them is, having been previously evaluated in the group session.
  • Relaxation session: this will be carried out by means of audio that will be posted on the platform and that the patient will be able to perform simultaneously.
  • Empowerment session: audio sessions that will deal with those needs that frequently arise after breast surgery in their daily lives, focusing on limiting beliefs (e.g. fear of moving), positive thoughts and information extracted from the motivational interview that should be developed.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Disabilities of the Arm, Shoulder and Hand Score (DASH)
Time Frame: 12 weeks
Global assessment of the functionality of the upper limb,
12 weeks
Disabilities of the Arm, Shoulder and Hand Score (DASH)
Time Frame: 3 months
Global assessment of the functionality of the upper limb,
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
European organization for research and treatment of cancer quality life questionnaire core 30. (QLQ-C30-B23)
Time Frame: 12 weeks
Questionnaire to assess quality of life in cancer patients. Module B23, which is specific to breast cancer, will be used.
12 weeks
Range Of Motion (ROM)
Time Frame: 12 weeks
Goniometry of joint range
12 weeks
Tampa Scale for Kinesiophobia (TSK-11SV)
Time Frame: 12 weeks
The TSK is an 11-item self-report measure related to fear of movement and re-injury from movement.
12 weeks
Brief Pain Inventory (BPI)
Time Frame: 12 weeks
The BPI is a multidimensional pain assessment tool that provides information on pain intensity and its interference with patients' daily activities. It also assesses the description, the location of pain and the level of relief provided by the treatment.
12 weeks
Hospital Anxiety and Depression Scale (HADS)
Time Frame: 12 weeks
Questionnaire to measure levels of anxiety and depression in these people.
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 2, 2021

Primary Completion (Actual)

October 28, 2024

Study Completion (Actual)

December 30, 2024

Study Registration Dates

First Submitted

April 6, 2021

First Submitted That Met QC Criteria

April 6, 2021

First Posted (Actual)

April 8, 2021

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 24, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • PI-2021-3

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Active Comparator: Group 1. Conventional treatment

Subscribe